

University of Groningen

The role of B cells in giant cell arteritis and polymyalgia rheumatica

Graver, Jacolien

DOI:
[10.33612/diss.236809207](https://doi.org/10.33612/diss.236809207)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Graver, J. (2022). *The role of B cells in giant cell arteritis and polymyalgia rheumatica*. University of Groningen. <https://doi.org/10.33612/diss.236809207>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

5

Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica

Graver JC¹, Abdulahad WH¹, van der Geest KSM¹, Heeringa P², Boots AMH¹, Brouwer E¹, Sandovici M¹

¹ Department Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

² Department of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Journal of Autoimmunity; 2021; 123:102684

Abstract

Objective: B-cells are present in the inflamed arteries of giant cell arteritis (GCA) patients and a disturbed B-cell homeostasis is reported in peripheral blood of both GCA and the overlapping disease polymyalgia rheumatica (PMR). In this study, we aimed to investigate chemokine-chemokine receptor axes governing the migration of B-cells in GCA and PMR.

Methods: We performed Luminex screening assay for serum levels of B-cell related chemokines in treatment-naïve GCA (n=41), PMR (n=31) and age- and sex matched healthy controls (HC, n=36). Expression of chemokine receptors on circulating B-cell subsets were investigated by flow cytometry. Immunohistochemistry was performed on GCA temporal artery (n=14) and aorta (n=10) and on atherosclerosis aorta (n=10) tissue.

Results: The chemokines CXCL9 and CXCL13 were significantly increased in the circulation of treatment-naïve GCA and PMR patients. CXCL13 increased even further after three months of glucocorticoid treatment. At baseline CXCL13 correlated with disease activity markers. Peripheral CXCR3⁺ and CXCR5⁺ switched memory B-cells were significantly reduced in both patient groups and correlated inversely with their complementary chemokines CXCL9 and CXCL13. At the arterial lesions in GCA, CXCR3⁺ and CXCR5⁺ B-cells were observed in areas with high CXCL9 and CXCL13 expression.

Conclusion: Changes in systemic and local chemokine and chemokine receptor pathways related to B-cell migration were observed in GCA and PMR mainly in the CXCL9-CXCR3 and CXCL13-CXCR5 axes. These changes can contribute to homing and organisation of B-cells in the vessel wall and provide further evidence for an active involvement of B-cells in GCA and PMR.

Introduction

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are frequently overlapping inflammatory diseases occurring at an older age¹. PMR is diagnosed in up to 60% of GCA patients^{2,3}, whereas the prevalence of GCA in PMR varies between 5 and 30%⁴. GCA is characterized by inflammation of the medium- and large arteries, while PMR is characterized by inflammation primarily of the synovial tissue of shoulders and hips. Dependent on which arteries are involved, GCA leads to cranial symptoms like headache (temporal artery; TA), or more systemic symptoms like weight loss and low-grade fever (aorta and its proximal branches)⁵. A complication of GCA is the formation of an aortic aneurysm. PMR is characterized by pain and stiffness mainly in the shoulder and hip girdle^{2,3}.

The pathogenesis of both diseases is incompletely understood. When GCA is suspected, the TA is easily accessible for a diagnostic biopsy, while the aorta or other large arterial branches are usually not approached for histological investigation. Based on studies of the TA, GCA is regarded as a granulomatous disease mainly mediated by T-cells and macrophages⁶. So far, the inflammatory processes in the TA and aorta are considered to be the same, but studies in GCA aorta are scarce.

B-cells have long been neglected in GCA research because so far no disease-specific auto-antibodies have been found and because early studies showed a relative low number of B-cells in the TA^{7,8}. In more recent studies we and others have clearly documented the presence and organisation of B-cells in both the TA and aorta of patients with GCA⁹⁻¹¹. Notably, the inflamed aorta of GCA patients contained high numbers of B-cells, even outnumbering T-cells¹¹. Scant information is available about B-cells in PMR synovial tissue. One study reported that B-cells were mostly absent in synovium biopsies of the shoulder in active PMR patients¹². Also, it has been clearly demonstrated that circulating B-cells are altered during the disease course in both GCA and PMR¹³⁻¹⁶. B-cell numbers were reduced during active disease and correlated inversely with disease activity markers. Glucocorticoid (GC) treatment, which remains standard of care in both GCA and PMR, normalized B-cell numbers¹⁴⁻¹⁶ without repopulation by newly produced B-cells or compensatory hyperproliferation¹³, indicating B-cell extravasation or marginalization during active disease and redistribution to circulation upon treatment. In addition, the returning effector B-cells demonstrated an enhanced capacity to produce the pro-inflammatory cytokine Interleukin (IL)-6¹³. Collectively, these data clearly document B-cell presence in GCA arteries, B-cell trafficking between the tissues and blood in GCA and PMR, and the capacity of B-cells to produce inflammatory cytokines in these two related diseases.

The specific mechanisms governing migration and organization of B-cells in GCA are largely unknown but leukocyte homing to tissues is generally mediated through

chemotactic gradients of chemokines. Chronic inflammatory and autoimmune diseases have been associated with disturbed production of chemokines¹⁷⁻¹⁹. B-cells express multiple chemokine receptors and can therefore migrate in response to several chemokines. Chemokines C-X-C motif receptor (CXCR)3 is expressed on the surface of B-cells and binds to the CXC ligands (CXCL)9, -10, and-11. This axis regulates migration towards the site of inflammation and is also involved in cell activation and differentiation²⁰. Another chemokine, CXCL13, was originally called B-cell chemo-attractant because together with its receptor, CXCR5, it exerts important functions in lymphoid neogenesis, B-cell homing and B-cell differentiation²¹.

Here we aimed to characterize the chemokine-chemokine receptor axes involved in the migration of B-cells in GCA and PMR in order to understand their migration patterns and to gain further insights into the role of B-cells in the pathogenesis of these diseases. To this end, various chemokines, chemokine receptor expression by B-cells and B-cell differentiation subsets were measured in the circulation of both GCA and PMR patients and compared to age- and sex-matched healthy controls (HC). In addition, TA biopsies and aorta tissue of GCA patients, and aorta tissue of atherosclerosis patients were studied for local chemokine and chemokine receptor expression with a focus on the CXCL9-CXCR3 and CXCL13-CXCR5 axes.

Methods

Study populations

Forty-one GCA patients and 31 PMR patients participated in the cohort study (Table 1). All were newly-diagnosed patients who did not take GC or other disease modifying anti-rheumatic drugs at pre-treatment assessment. The diagnosis of GCA was based on a positive TA biopsy and/or a positive 18F-fluorodeoxyglucose-positron emission computer tomography (FDG-PET-CT) scan. Twenty-seven of the GCA patients fulfilled the 1990 ACR criteria as these criteria are mainly useful for GCA with temporal artery involvement. The remaining 14 GCA patients did have a positive FDG-PET-CT scan. Twenty-three of the 31 PMR patients fulfilled the Chuang criteria and 29 PMR patients had a positive FDG-PET-CT scan. The 2 PMR patients without an FDG-PET-CT scan did fulfil the Chuang criteria. The PMR patients had neither GCA symptoms and signs nor vasculitis on imaging. Cross-sectional data of 36 age- and sex-matched healthy controls (HCs) selected from our SENEX cohort was included in this study. These are healthy individuals older than 50 years of age recruited from the general population of the north part of the Netherlands. At inclusion, the HCs had no relevant past and present diseases and did not take any immunosuppressive drugs. All subjects provided informed consent, and samples were obtained in compliance with the Declaration of Helsinki. The study was approved by the

institutional review board of the University Medical Center Groningen (METc2012/375 for HC and METc2010 for GCA and PMR). PBMC samples of subpopulations, consisting of 18 GCA patients, 10 PMR patients and 25 age- and sex-matched HC, were used for flow cytometric analysis/experiments. Detailed characteristics of these subpopulations are described in supplementary table 1.

Luminex for measurement of chemokines in circulation

CXCL9 and CXCL13 were quantified in serum as part of a human premix magnetic Luminex screening assay kit (R&D systems), which also included CCL19, CCL21, CXCL10, CXCL11, and CXCL12. The assay was read on a Luminex Magpix instrument (Luminex) and data were analysed with xPONENT 4.2 software (Luminex).

Flow cytometry for the analysis of circulating B-cell subsets and chemokine receptor expression

Absolute numbers of circulating B-cells were measured in fresh EDTA blood samples using the Beckton Dickinson Multitest Trucount method, as described by the manufacturer. Data were acquired on a FACS Canto-II (BD) and analysed with FACSCanto Clinical Software (BD). Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood with Lymphoprep (Axis-shield) and frozen in 10% DMSO/FCS medium. The PBMCs were stored in liquid nitrogen for future analysis. For flow cytometry analysis, cryopreserved PBMCs were thawed and 2 million cells were labelled with fluorochrome-conjugated antibodies for B-cell subset markers and chemokine receptor expression (see supplementary table 2 for a list of used antibodies). Samples were measured using an LSR-II flow cytometer (BD) and data were analysed using Kaluza software (BD). B-cells were defined as CD19⁺ cells and divided into seven subsets: transitional (CD38^{high}CD27⁻), naïve (CD38^{low/-}CD27⁻), unswitched memory (CD27⁺IgD⁻IgM⁺), switched memory (CD27⁺IgD⁻IgM⁻), IgM only memory (CD27⁺IgD⁻IgM⁺), plasmablasts (CD27^{high}CD38^{high}) and double negative B-cells (CD27⁻CD38⁻) (See supplementary data, figure 1 for gating strategy). Dead cells were excluded by using fixable viability dye and expression of chemokine receptors was determined for total B-cells and for each aforementioned specific subset. Gates were based on Fluorescence minus one controls and isotype controls.

Immunohistochemistry for detection of arterial B-cells, chemokines and chemokine receptors

TA (n=14) and aorta tissue (n=10) of GCA patients was formalin fixed, paraffin embedded and sectioned at 3 µm thickness. For comparison, aorta tissue (n=10) of atherosclerotic patients with an aortic aneurysm were also stained. Consecutive sections were deparaffinized and rehydrated after which antigen retrieval and endogenous peroxidase block were performed. Sections were incubated with anti-human antibodies for the detection of

the following markers: CD20, CXCL9, CXCL13, CXCR3, and CXCR5 (supplementary table 3). Subsequently, tissues were incubated with secondary antibodies, 3,3'-Diaminobenzidine (DAKO, Denmark) for peroxidase activity detection and counterstained with hematoxylin (MERCK, Kenilworth, NJ, USA). Tonsil was used as positive control tissue and appropriate isotype control stainings were performed. All stained tissue sections were scanned using a Nanozoomer Digital Pathology Scanner (NDP Scan U 10074-01, Hamamatsu Photonics K.K.) before being analyzed. Representative areas, containing infiltrating cells and if present B-cells, were semi-quantitatively scored on a five-point scale (0-4) with 0 = no positivity, 1 = occasional positivity (0-1%), 2 = mild positivity (>1-20%), 3 = moderate positivity (>20-50%), 4 = high positivity (>50%).

Statistical analysis

Non-parametric tests were used for data analysis as data was not normally distributed. For comparison of the three groups the Kruskal-Wallis test was performed and, where appropriate, for comparison of two groups the Mann-Whitney U test was performed. Paired samples (pre-treatment and after 3 months of treatment) were compared with the Wilcoxon signed rank test. Correlations were assessed with the Spearman's rank correlation coefficients. GraphPad Prism 8.0 software was used for analysis and p-values of less than 0.05 (2-tailed) were considered statistically significant.

Results

Serum chemokine levels in GCA and PMR patients compared to HC

First, serum levels of several chemokines involved in B-cell migration were measured in order to identify which chemokine pathways are altered and thus are possibly involved in B-cell migration in GCA and PMR. Figure 1A depicts in a heatmap the differences in serum chemokine levels between the three study groups. In GCA, CCL19 and CCL21 were significantly elevated compared to HC. The levels of CCL21 in GCA were also significantly elevated when compared to PMR patients. The chemokine CXCL9 was significantly elevated in both patient groups (figure 1B). Although CXCL10 and CXCL11 were slightly higher, especially in GCA patients, they were not significantly altered compared to HC. PMR patients showed significantly lowered CXCL12 levels compared to both HC and GCA patients. CXCL13 was increased in both patient groups compared to HC and CXCL13 levels in PMR were significantly elevated compared to GCA (figure 1C). CXCL13 correlated with baseline levels of disease activity markers ESR (GCA and PMR) and CRP (only in PMR) (figure 1F). Serum chemokine levels did not differ between cranial GCA and large-vessel GCA/PMR patients. More specifically, no difference was seen within the GCA group between the patients with and without headache, jaw claudication, vision loss and leg




Figure 1. Chemokine expression in the circulation of GCA (n=41), PMR (n=31) and HC (n=36). (A) Heatmap depicting median fold-change compared to HC with *= $p < 0.05$ compared to HC, $\leftrightarrow = p < 0.05$ between GCA and PMR. (B-C), Baseline (pre-treatment) levels of respectively CXCL9 and CXCL13 for HC, GCA and PMR. (D-E), Change in circulating chemokine levels between baseline and 3 months (GC-treated) for respectively CXCL9 and CXCL13 in both GCA (n=35) and PMR (n=23). (F) Correlations of CXCL13 with disease activity markers ESR (GCA and PMR) and CRP (PMR).

claudication. There was a significant difference ($p = 0.04$) regarding the arm claudication, whereby the group with arm claudication had a lower level of CXCL9. However the group with arm claudication was small ($N=5$).

After 3 months of GC treatment, the levels of all chemokines measured either normalized to HC levels or showed a tendency towards normalization (see for example CXCL9, figure 1D). The only exception was CXCL13, which was already increased at baseline and further increased after 3 months in both GCA and PMR patients (figure 1E).

Peripheral B-cell subset distribution and chemokine receptor expression on circulating B-cells of GCA, PMR and HC

To gain insight into which B-cells subsets migrate in GCA and PMR we analyzed the distribution of B-cell subsets in the circulation in conjunction with chemokine receptor expression on these specific B-cell subsets. In circulation and before treatment, the total B-cell number in GCA and PMR tended to be lower compared to HC although this difference did not reach statistical significance (see Table 1 and individual values included in supplementary figure 2). Analysis of the different B-cell differentiation subsets revealed altered distribution patterns compared to HC (figure 2A). GCA patients showed lowered switched memory B-cells while PMR patients showed elevated double negative B-cells and plasmablasts. After 3 months of GC-treatment, transitional B-cells were almost depleted in both patient groups (figure 2B and 2C) while, specifically for GCA, all memory B-cells subsets increased.

Next, we focused on the expression of the chemokine receptors by circulating B-cells for which the corresponding chemokines were altered in the sera of GCA or PMR patients. The percentage of B-cells expressing CXCR3, CXCR4, CXCR5 or CCR7 was lowered in GCA and PMR patients compared to HC (figure 3A). This decrement only reached statistical significance for the PMR patients and here a negative correlation between CXCR5+ B-cells and CRP (figure 3B) was observed. Similar negative correlations were also observed in PMR between CXCR4+ B-cells and CRP ($r = -0.77$, $p < 0.01$) and CCR7+ B-cells with CRP ($r = -0.82$, $p < 0.01$). Looking into specific B-cell subsets, we found that the percentage and absolute number of CXCR3+ switched memory B-cells were significantly lowered in both patient groups compared to HC (figure 3C). This finding was also true for the percentage of CXCR5+ switched memory B-cells (figure 3D). There was a large variation especially in the CXCR3+ switched memory B-cells, not only in the patient groups but also in the healthy controls. In the healthy controls a negative correlation was found between the CXCR3+ switched memory B-cells and age for both the absolute numbers ($r = -0.70$, $p < 0.01$) and frequencies ($r = -0.41$, $p = 0.05$). This was also the case for the CXCR5+ switched memory B-cells and age for both the absolute numbers ($r = -0.50$, $p = 0.02$) and frequencies ($r = -0.46$, $p = 0.03$). However, no such correlation was documented in the GCA and PMR patient groups. We found inverse correlations between

CXCL9 and CXCR3+ B-cells, and between CXCL13 and CXCR5+ B-cells in GCA patients (figure 3E-F). The same inverse correlations were observed in GCA patients for CXCL9 with CXCR3+ memory B-cells (figure 3G), CXCL9 with switched memory B-cells (figure 3H), and for CXCL13 with CXCR5+ switched memory B-cells (figure 3I). These correlations were only observed for the GCA patients and not found in the PMR patient group.

Chemokine receptor expression on circulating B-cells did not significantly differ between cranial GCA and large vessel GCA at baseline. Also, there were no significant correlations between specific CXCR3+ B cells and CXCR5+ B-cells subsets, and these clinical parameters. An inverse correlation was observed between total B-cell counts and CXCL9, as well as between total B-cell counts and CXCL13 in large vessel-GCA only (data not shown).

Table 1. Pre-treatment characteristics of newly diagnosed giant cell arteritis (GCA), polymyalgia rheumatica (PMR) patients and age-matched healthy controls (HC).

	HC	GCA	PMR	KW/ Chi- square	p-value HC vs GCA	p-value HC vs PMR	p-value GCA vs PMR
n	34	41	31				
age in years; median (range)	71 (52-85)	71 (52-84)	73 (54-82)	NS			
Females (%)	23 (68)	28 (70)	17 (55)	NS			
TA positive/performed	NA	19/25	0/4				
FDG-PET-CT positive for GCA/PMR/ GCA+PMR	NA	18/0/11	0/29/0				
Fulfilled ACR criteria (GCA); Yes/No	NA	27/14	NA				
Fulfilled Chuang criteria (PMR); Yes/ No	NA	NA	23/8				
CRP mg/L; median (range)	5 (1,7-11)	49 (2,2-215)	32,5 (3,2-127)	<0,0001	<0,0001	<0,0001	NS
ESR mm/h; median (range)	11 (2-24)	81 (7-121)	57 (7-109)	<0,0001	<0,0001	<0,0001	<0,05
Hb mmol/L; median (range)	8,7 (7,3-10)	7,3 (5,5-8,5)	7,8 (6,2-9,3)	<0,0001	<0,0001	<0,0001	<0,05
Lymphocytes $10^9/L$; median (range)	1,96 (0,69-2,72)	1,67 (0,76-3,19)	1,5 (0,8-2,85)	NS			
CD19+ B-cells $10^9/L$; median (range)	0,20 (0,07-0,49)	0,15 (0,03-0,54)	0,17 (0,06-0,44)	NS			




Figure 2. Dynamics in B-cell subsets before (A) and during 3 months follow-up after GC treatment for GCA (n=18) (B) and PMR (n=10) (C). B-cell subset cell counts are expressed in radar plots as median fold-change compared to healthy control (n=25). #=sign. difference between HC and PMR, *=sign. difference between HC and GCA, *=sign. difference between baseline and 3 months.

Local expression of migration axes CXCL9-CXCR3 and CXCL13-CXCR5 in inflamed GCA arteries and co-localization with B-cells

We next investigated local arterial expression of the B-cell related chemokines and chemokine receptors that were altered in the circulation of GCA and PMR patients. CD20+ B-cell presence was confirmed by immunohistochemistry in TA and aorta of GCA patients (figure 4A and 4F). The chemokines CXCL9 and CXCL13 were both highly expressed in the TA and aorta tissues of GCA patients (figure 4B and 4D). In TA tissue the chemokines were equally expressed in all three layers of the vessel wall (adventitia, media and intima) while in the aorta the chemokine expression was mostly observed in the media and adventitia (figure 4G and 4I). The expression of both chemokines was higher in GCA than in atherosclerotic aorta. The accompanying receptors for CXCL9 and CXCL13, CXCR3 and CXCR5 respectively, were also highly expressed in the inflamed GCA arteries (figure 4C and 4E). Notably, the expression of the chemokines and their receptors was detected in the same regions of the vessel wall (figure 4G-J). Moreover, almost all




Figure 3. Chemokine receptor expression on circulating B-cells and correlations with their corresponding chemokines. (A) heatmap depicting median fold-change compared to HC with $*=p<0.05$ compared to HC, $\Leftrightarrow= p<0.05$ between GCA and PMR. (B) negative correlation in PMR patients between CXCR5+ B-cells and disease activity marker CRP. (C) Percentage and absolute number of CXCR3+ switched memory B-cells for GCA and PMR patients. (D) Percentage and absolute number of CXCR5+ switched memory B-cells for GCA and PMR patients. Negative correlation in GCA patients between CXCR3+ B-cells and CXCL9 (E), CXCR5+ B-cells and CXCL13 (F), CXCR3+ memory B-cells and CXCL9 (G), CXCR3+ switched memory B-cells and CXCL9 (H) and CXCR5+ switched memory B-cells and CXCL13 (I).

B-cell clusters were located in areas with high chemokine and chemokine receptor expression. Co-expression of CXCL9 and CXCR3 was detected in all of the B-cell clusters in TA and in the vast majority of the B-cell clusters in aorta. Co-expression of CXCL13 and CXCR5 was also detected in all of the TA B-cell clusters and in the vast majority of the B-cell clusters located in the aorta. Because CXCR3 and CXCR5 can also be expressed by other inflammatory cell types, we confirmed expression of these chemokine receptors by B-cells with double immunostainings using PAX5 (nuclear B-cell marker) together with CXCR3 (Figure 4K) or CXCR5 (Figure 4L).




Figure 4. Local expression of B-cells, chemokines and chemokine receptors in inflamed GCA arteries. Single-staining representative immunohistochemistry showing expression of (A) CD20 (B-cells), (B) CXCL9, (C) CXCR3, (D) CXCL13 and (E) CXCR5 in both TA and aorta with an overview image (left panel) and a higher magnification picture (right panel). For references, the different layers of the vessel wall are indicated in the CD20 staining, with int=intima, med=media and adv=adventitia. (F-J), semi-quantitative scoring of the TA (n=14) and aorta (n=10) of GCA patients in comparison to the atherosclerotic aorta (n=10) for all stainings. Median (line) and IQR are shown (K), double-staining of PAX5 (B-cells, red) and CXCR3 (blue). (L), double-staining of PAX5 (B-cells, red) and CXCR5 (blue). The white arrows point towards CXCR3+ and CXCR5+ B-cells.

Discussion

B-cells represent a dynamic cell population in GCA and PMR as demonstrated by changes of B-cells in both peripheral blood of GCA and PMR patients as well as in the inflamed arterial wall in GCA. In search for the mechanisms governing the trafficking of B-cells in GCA and PMR, we document here modulation of several B-cell-related chemokines, including CXCL9 and CXCL13, in the serum of GCA and PMR patients before treatment




Figure 5. Graphical representation of the main study findings in GCA (left) and PMR (right). Local expression of the chemokines CXCL9 and CXCL13 was observed with immunohistochemistry in both inflamed temporal artery and aorta of GCA patients. B-cells that had infiltrated the inflamed arteries expressed the corresponding CXCR3 and CXCR5 receptors. In the circulation, alterations in chemokine levels were observed in active, untreated GCA and PMR patients. CXCL9 and CXCL13 were increased in the circulation of both patient groups. CCL19 and CCL21 were found increased in GCA patients while CXCL12 was decreased only in PMR patients. B-cell subset distribution was also altered in the circulation of both GCA and PMR patients. Lowered total switched memory B-cells, CXCR3+ memory B-cells and CXCR5+ memory B-cells were detected in the circulation of GCA patients suggesting that these B-cells migrate towards inflamed arteries. In PMR patients elevated double negative B-cells and plasmablasts were observed in the circulation. When focusing on chemokine receptor expression by B-cells, PMR patients had lowered CXCR3+, CXCR4+, and CXCR5+ B-cells. It is still unclear if these B-cells migrate towards inflamed synovia or the lymphatic system in PMR patients.

and during follow-up. Accordingly, we observed changes in B-cell subsets expressing the chemokine receptors CXCR3 and CXCR5 in the peripheral blood of patients with GCA and PMR before treatment. Moreover, we document the presence of the B-cell related chemokines CXCL9 and CXCL13 at the site of vascular infiltration with CXCR3+ and CXCR5+ B-cells, respectively, in GCA. A graphical representation of the main study findings is given in figure 5.

B-cells respond and migrate towards the chemokines CXCL9 and CXCL13 produced at the site of inflammation by virtue of the CXCR3 and CXCR5 receptors, respectively. We observed high expression of CXCL9 and CXCL13 protein in all layers of the TA and in the medial and adventitial layer of the aorta as assessed by immunohistochemistry. The expression of these chemokines coincided with expression of the corresponding CXCR3 and CXCR5 receptors throughout the entire tissue, including the areas with B-cell clusters. Thus B-cells in GCA arteries express the CXCR3 and CXCR5 receptors and are mostly located in the adventitia and media where the corresponding chemokines are also present, supporting an ongoing tissue-infiltrating migratory process. In the most inner part of the neointima there was less CXCL9 and CXCL13 protein expression, which coincided with a paucity of B-cell intimal infiltration.

The ligands of CXCR3, including CXCL9, are commonly produced at peripheral sites to attract lymphocytes²². CXCR3 is also expressed on T-cells and the CXCL9-CXCR3 axis is important for the recruitment of CD4+ T-cells and CD8+ T-cells, known to be active in the arteries affected by GCA²³. Previously, in an ex-vivo TA culture system it was also shown that the CXCR3 receptor ligands, CXCL9, CXCL10 and CXCL11, were increased in GCA biopsies compared to negative biopsies²⁴. Blocking or addition of IFN γ to the culture either decreased or increased the production of these chemokines, respectively. Moreover, migration of PBMCs was stimulated by chemokine-rich supernatant of vascular smooth muscle cells exposed to IFN γ and this effect was abated by CXCR3 antagonism. This, together with our data, strongly indicates that the CXCL9-CXCR3 axis is actively contributing to both T- and B-cell migration in GCA.

In accordance with our protein findings in TA, mRNA levels of CXCL13 and CXCR5 were previously found to be increased in the GCA TA that contained B-cells organized into tertiary lymphoid organs (TLOs)⁹. Myofibroblasts were considered as a possible source of the CXCL13 in TA of the GCA patients⁹, however we did not observe much CXCL13 expression in the regions with intimal hyperplasia where myofibroblast are present. Another source of CXCL13 is represented by the follicular dendritic cells (FDC), which are present in the TLOs of GCA TA and aorta^{11,22}. The main immune function of CXCL13 is inducing trafficking and positioning of CXCR5+ B-cells and CXCR5+ T-cells towards B-cell follicles in lymphoid tissues, including TLOs²². The present study demonstrates that there is widespread chemokine expression and chemokine receptor expression by lymphocytes in TA and in the aortic TLOs. This finding supports the notion of an

ongoing inflammatory process also in the aorta affected by aneurysm formation in GCA patients. In addition, the TLOs contain high endothelial venules (HEV), which are specialized venules that facilitate lymphocyte extravasation. The presence of HEV in combination with the observed chemokine expression at the TLOs likely aid the ongoing inflammation.

The observed increase in serum CXCL13, before and during GC-treatment, and the correlations between CXCL13 and disease activity markers before treatment in both GCA and PMR are remarkable. CXCL13 and its receptor CXCR5 play a central role in the organization of lymphoid tissue, are essential for the formation of TLOs in multiple autoimmune diseases and can also cause local memory B-cell differentiation²¹. CXCL13 is considered to be a serum biomarker for germinal center activity²⁵ and it has been associated with unfavorable disease prognosis in multiple diseases^{21,26-28}. TLOs with FDCs and germinal centers are indeed observed in the GCA TA and aorta and could contribute to systemic CXCL13 levels. The source of the increased CXCL13 in PMR is obscure in the absence of synovial tissue analysis. The further increase of CXCL13 levels during treatment (3 months) in both diseases is intriguing and spikes interest in CXCL13 level dynamics during a longer follow-up period. In rheumatoid arthritis (RA) patients, B-cell depletion therapy led to a reduction in peripheral and systemic levels of CXCL13 which was followed by a subsequent increase upon B-cell repopulation²⁹. Next to CXCL13, the chemokine CCL19, which we also found increased in the circulation of GCA patients, is implicated in TLO formation³⁰. Blockade of specific chemokine-chemokine receptor pathways have not been tested so far in GCA/PMR but could be an appealing strategy to diminish B- and T-cell mediated damage in GCA. In the MRL/lpr mice model of systemic lupus erythematosus, treatment with CXCL13-blocking monoclonal antibodies diminished the renal damage, the level of circulating anti-dsDNA antibodies and immune complex deposition in the kidneys³¹.

The present study also demonstrates alterations in circulating B-cells in both GCA and PMR. In line with previous reports^{13,14,32}, the total B-cell numbers were lowered before treatment in GCA and PMR patients although this did not reach statistical significance for the patients included in this study. We did observe an increase in circulating B-cells at the 3-months follow up timepoint as reported before^{13,14}. When looking at specific B-cell subsets, total CXCR3+ and CXCR5+ B-cells were significantly lowered in PMR patients but this did not reach statistical significance in GCA. However, the CXCR3+ and CXCR5+ switched memory B-cells were significantly lowered in both diseases, suggesting an increased rate of CXCR3+ and CXCR5+ switched memory B-cell trafficking during active disease in both GCA and PMR as compared to HCs. There was a large variation in the CXCR3+ switched memory B-cells and CXCR5+ switched memory B-cells in all groups. While in the healthy controls this may be explained by a decrease of specific B-cell subsets with aging, no such negative correlations were found in the patient groups. The

variation in the patient groups may be related to heterogeneity in the local chemokine production at the site of inflammation and consequently, a heterogeneity in the migration of the B-cells expressing the corresponding chemokine receptor. We found strong inverse correlations between the serum levels of chemokines and the chemokine receptor expressing total B-cells, CD27+ memory B-cells and switched memory B-cells in GCA. These findings indicate higher chemokine expression levels in tissue compared to circulation allowing migration towards the inflamed vessel wall of specific B-cells subsets according to the chemokine gradient. B-cells were also observed in synovial tissue of RA patients, along with CXCL9, CXCR3, CXCL13 and CXCR5, suggesting that these pathways are also important for B-cells migration and organization in the RA synovium³³. The lowered switched memory B-cells observed in untreated GCA patients, together with the increase in all memory subsets at three months and simultaneous decrease in transitional B-cells, suggest trafficking specifically of memory B-cells. The sharp decrease of transitional B-cells in both patient groups after three months is likely caused by the GC usage as it was previously shown that especially early B-cell progenitors are sensitive to GC treatment³⁴. Double negative (DN) B-cells, which were increased in the circulation of PMR patients, are believed to be related to aging, senescence and the senescence-associated secretory phenotype³⁵. Increased DN B-cells were previously documented in several auto-immune disease such as early and established RA³⁶, multiple sclerosis (MS)³⁷ and SLE³⁸. However, it is unknown whether these cells are also present at the local site of inflammation in PMR or what causes their increase in the circulation of PMR patients but not of GCA patients, as both diseases are associated with older age.

Regarding the clinical phenotype of our patient groups and the B-cell related chemokine-chemokine receptor axes, we found significant lower CXCL9 levels at baseline in the GCA patients with arm claudication. However, as the group with arm claudication was small, this finding should be confirmed and further investigated in a larger group of patients. An inverse correlation was observed between total B cell counts and CXCL9, as well as between total B cell counts and CXCL13 in large vessel-GCA only. Previously, Ciccia et al. documented a positive correlation between the number of organized B cells into tertiary lymphoid organs in the temporal artery and parameters of systemic inflammatory response⁹. There was no correlation with age, duration of symptoms or specific GCA features such as headache or ischemia. Further research into the function of specific B-cell subsets, especially regarding cytokine production is needed to dissect differences between clinical GCA/PMR phenotypes and possible different underlying pathophysiological mechanisms in disease subsets.

Our work further supports an active role of B-cells in the pathogenesis of GCA/PMR. Thus far no disease specific auto-antibodies have been documented in GCA/PMR. There is however ample evidence that the B-cells can also play an antibody-independent, cytokines-mediated role in autoimmune and autoinflammatory diseases. Previous work

from our group ³⁸ demonstrated that the circulating effector B-cells (likely returning from the sites of inflammation to the peripheral blood upon glucocorticoid-induced remission) have an enhanced capacity to produce IL-6 in GCA and PMR patients. Given the important role played by IL-6 in the pathogenesis of GCA and the new insights into the B-cell compartment in GCA/PMR, it would be interesting to investigate the therapeutic effect of B-cell depleting therapy in GCA/PMR. We currently investigate the role of B-cells in the production of other cytokines. B-cells are also capable of antigen presentation at the site of tissue inflammation. This mechanism has, to the best of our knowledge, not yet been investigated in GCA and PMR.

There are several limitations of our study. First, chemokine gradients determine the migration of chemokine sensitive cells. As the chemokines levels in biopsies and circulation were not measured with the same technique, a direct chemokine gradient comparison was not feasible. Second, the studied chemokines and chemokine receptors are not exclusive for B-cell trafficking and are also used by other lymphocytes such as T-cells. Third, this study did not include local expression of B-cells, chemokines and chemokine receptors in PMR patients as synovial biopsies of PMR patients are not routinely taken for diagnostic purposes.

Conclusion

In conclusion, the data presented here support an important role for the CXCL9-CXCR3 and CXCL13-CXCR5 axes in shaping the peripheral B-cell compartment in GCA and PMR and organisation of B-cells in TLOs in GCA. This study provides further grounds for an active involvement of B-cells in the pathogenesis of GCA and PMR.

Acknowledgements

The authors thank Johan Bijzet and Daphne Wolberts for their support with the execution of the Luminex.

References

1. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. *Rheumatology* 2017;56(4):506-512.
2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. *Lancet*. 2008;372:234-245.
3. Salvarani C, Gabriel SE, Michael O'Fallon W, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. *Arthritis Rheum*. 1995;38:369-373.
4. Lavado-Pérez C, Martínez-Rodríguez I, Martínez-Amador N, Banzo I, Quirce R, Jiménez-Bonilla J, et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. *Rev Esp Med Nucl Imagen Mol*. 2015;34:275-281.
5. Van Der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic accuracy of symptoms, physical signs, and laboratory tests for giant cell arteritis: a systematic review and meta-analysis. *JAMA Intern Med*. 2020;180:1295-1304.
6. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. *Nat Rev Rheumatol*. 2013;9:731-740.
7. Martinez-Taboada V, Brack A, Hunder GG, Goronzy JJ, Weyand CM. The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. *J Rheumatol*. 1996;23:1011-1014.
8. Andersson R, Jonsson R, Tarkowski A, Bengtsson BÅ, Malmvall BE. T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis. *Ann Rheum Dis*. 1987;46:915-923.
9. Ciccia F, Rizzo A, Maugeri R, Alessandro R, Croci S, Guggino G, et al. Ectopic expression of CXCL13, BAFF, APRIL and LT- β is associated with artery tertiary lymphoid organs in giant cell arteritis. *Ann Rheum Dis*. 2017;76:235-243.
10. Graver JC, Sandovici M, Diepstra A, Boots AMH, Brouwer E. Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. *Ann Rheum Dis*. 2018;77:e16.
11. Graver JC, Boots AMH, Haacke EA, Diepstra A, Brouwer E, Sandovici M. Massive B-Cell infiltration and organization into artery tertiary lymphoid organs in the aorta of large vessel giant cell arteritis. *Front Immunol*. 2019;10:83.
12. Meliconi R, Facchini A, Salvarani C, Macchioni P, Nuova ASM, Emilia R, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. quantitative analysis and influence of corticosteroid treatment. *Arthritis Rheum*. 1996;39:1199-1207.
13. Van Der Geest KSM, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. *Arthritis Rheumatol*. 2014;66:1927-1938.
14. van Sleen Y, Graver JC, Abdulahad WH, van der Geest KSM, Boots AMH, Sandovici M, et al. Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica. *Front Immunol*. 2019;10.
15. Uddhammar A, Roos G, Näsman B, Dahlqvist SR. Peripheral blood lymphocyte subsets in polymyalgia rheumatica. *Clin Rheumatol*. 1995;14:62-67.
16. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, et al. Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. *Arthritis Res Ther*. 2019;21.

17. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. *Blood*. 2000;95:3032-3043.
18. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med*. 2006;354.
19. Proost P, Struyf S, Van Damme J, Fiten P, Ugarte-Berzal E, Opdenakker G. Chemokine isoforms and processing in inflammation and immunity. *J Autoimmun*. 2017;85.
20. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. *Cancer Treat Rev*. 2018;63:40.
21. Kazanietz MG, Durando M, Cooke M. CXCL13 and its receptor CXCR5 in cancer: Inflammation, immune response, and beyond. *Front Endocrinol*. 2019;10:1-15.
22. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annu Rev Immunol*. 2014;32:659-702.
23. Samson M, Ly KH, Tournier B, Janikashvili N, Trad M, Ciudad M, et al. Involvement and prognosis value of CD8+ T cells in giant cell arteritis. *J Autoimmun*. 2016;72:73-83.
24. Corbera-Bellalta M, Planas-Rigol E, Lozano E, Terrades-García N, Alba MA, Prieto-González S, et al. Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. *Ann Rheum Dis*. Published online 2015:1-10.
25. Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, et al. CXCL13 is a plasma biomarker of germinal center activity. *Proc Natl Acad Sci U S A*. 2016;113:2702.
26. Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary sjögren's syndrome. *Arthritis Rheumatol*. 2015;67:3226-3233.
27. Lee H-T, Shiao Y-M, Wu T-H, Chen W-S, Hsu Y-H, Tsai S-F, et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. *J Rheumatol*. 2010;37:45-52.
28. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. *Brain Pathol*. 2004;14:164-174.
29. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. *Rheumatology* 2011;50:603-610.
30. Pickens SR, Chamberlain ND, Volin M V., Pope RM, Mandelin AM, II, et al. Characterization of CCL19 and CCL21 in rheumatoid arthritis. *Arthritis Rheum*. 2011;63:914.
31. Miyabe Y, Lian J, Miyabe C, Luster AD. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications. *Nat Rev Rheumatol*. 2019;15:731-746.
32. Alegria GC, Devauchelle-Pensec V, Renaudineau Y, Saraux A, Pers JO, Cornec D. Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica. *Rheumatol*. 2017;56:1401-1406.
33. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. *Arthritis Res Ther*. 2009;11:R149.
34. Lill-Elghanian D, Schwartz K, King L, Fraker P. Glucocorticoid-induced apoptosis in early B cells from human bone marrow. *Exp Biol Med*. 2002;227:763-770.

35. Frasca D, Diaz A, Romero M, Blomberg BB. Human peripheral late/exhausted memory B cells express a senescent-associated secretory phenotype and preferentially utilize metabolic signaling pathways. *Exp Gerontol.* 2017;87:113-120.
36. Moura RA, Quaresma C, Vieira AR, Gonçalves MJ, Polido-Pereira J, Romão VC, et al. B-cell phenotype and IgD-CD27⁻ memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. *PLoS One* 2017;12:e0182927.
37. Claes N, Fraussen J, Vanheusden M, Hellings N, Stinissen P, Wijmeersch B Van, et al. Age-associated B cells with proinflammatory characteristics are expanded in a proportion of multiple sclerosis patients. *J Immunol.* 2016;197:4576-4583.
38. Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel A V, Wang X, et al. distinct effector b cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. *Immunity.* 2018;49:725-739.e6.

Supplemental data

Supplementary Table 1. Pre-treatment characteristics of the population subset used for flow cytometric experiments including newly diagnosed, treatment-naive giant cell arteritis and polymyalgia rheumatica patients and aged healthy controls.


	HC	GCA	PMR	KW/ Chi-square	p-value HC vs GCA	p-value HC vs PMR	p-value GCA vs PMR
n	23	18	10				
age in years; median (range)	71 (52-85)	73 (52-84)	74 (64-82)	NS			
Females (%)	16 (70)	13 (72)	6 (60)	NS			
TA positive/performed	NA	9/12	0/1				
FDG-PET-CT positive for GCA/ PMR/GCA+PMR	NA	10/0/5	0/10/0				
Fulfilled ACR criteria (GCA); Yes/No	NA	11/7	NA				
Fulfilled Chuang criteria (PMR); Yes/ No	NA	NA	8/2				
CRP mg/L; median (range)	5 (1,7-5)	47 (4,7-138)	29 (3,2-105)	<0,0001	<0,0001	<0,0001	NS
ESR mm/h; median (range)	11 (2-23)	64 (7-116)	52 (30-109)	<0,0001	<0,0001	<0,0001	NS
Hb mmol/L; median (range)	8,6 (7,3-9,6)	7,2 (5,6-8,3)	7,7 (6,2-8,8)	<0,0001	<0,0001	<0,0001	NS
lymphocytes 10 ⁹ /L; median (range)	1,93 (1,09-2,67)	1,71 (0,76-3,01)	2,02 (1,34-2,85)	NS			
CD19+ B-cells 10 ⁹ /L; median (range)	0,21 (0,07-0,41)	0,16 (0,06-0,31)	0,26 (0,07-0,44)	NS			

Supplementary Table 2. Fluorochrome-conjugated antibodies for B-cell subset analysis and chemokine receptors expression


Antigen	Fluorochrome	Clone	Company
Fixable viability dye	eF506	-	eBioscience
CD19	BV786	SJ25C1	BD Biosciences
CD27	BV421	M-T271	BD Biosciences
CD38	APC-eF780	HIT2	eBioscience
IgD	BUV737	IA6-2	BD Biosciences
IgM	APC	Hi98	BD Biosciences
CXCR3	PE-Cy7	1C6	BD Biosciences
CXCR4	PE-CF594	12G5	BD Biosciences
CXCR5	BB515	RF8B2	BD Biosciences
CD86	BV711	2331 (FUN-1)	BD Biosciences
CD3	AF700	UCHT1	eBioscience
CD307d	PE	413D12	Biolegend
CD40	BV605	5C3	Biolegend
CCR2	PerCP-Cy5.5	K036C2	Biolegend

Supplementary table 3. Antibodies used for immunohistochemistry

Antigen	Isotype	Company	Dilution	Antigen retrieval
CD20	Mouse IgG2b	DAKO	1:50	pH=9
CXCL9	Rabbit IgG	Novus Biologicals	1:75	pH=9
CXCL13	Rabbit IgG	Novus Biologicals	1:50	pH=9
CXCR3	Mouse IgG2b	R&D systems	1:300	pH=9
CXCR5	Mouse IgG2b	R&D systems	1:200	pH=9



Supplementary Figure 1. Gating strategy for B-cell subsets. After eliminating death cells, B-cells were divided in the quadrant of Naïve, Double negative B-cells, Unswitched memory B-cells and Switched memory B-cells with the markers IgD and CD27. Naïve B-cells were further divided based on expression of CD38 into Transitional and Mature-Naïve B-cells. The switched memory population was further divided into IgM only memory B-cells, Switched Memory B-cells and Plasmablast by means of the markers IgM and CD38.



Supplementary Figure 2. Individual B-cell numbers for the studied patient groups. Left, all patient included and right, the subpopulation used for the flow cytometry analysis. Graphs depict individual values and the median (red line).

